Finance Featured

The Drugstore Era Is Over. CVS Just Made It Official.

CVS is splitting its 9,000 drugstores from Aetna and Caremark, unwinding the biggest vertical-integration bet in American healthcare. Why it's happening now, and what investors should watch before 2028.

Alpha One

09 Nov 2026 • 6 min read

On Wednesday morning, CVS Health announced it will tear itself in two. The company that spent two decades assembling America's largest healthcare conglomerate — drugstores, an insurance giant, the country's biggest pharmacy benefit manager, primary care clinics, home health — told investors it intends to separate into two independent, publicly traded companies by the first half of 2028.

One company keeps the machinery: Aetna's insurance business, the Caremark pharmacy benefit manager, the specialty drug operation, Oak Street Health's primary care clinics, and Signify Health's home-visit business. It keeps the CVS Health name and the current CEO, David Joyner.

The other company gets the stores. Roughly 9,000 retail pharmacies, the mail-order pharmacy, MinuteClinic, and a nearly 30,000-strong pharmacist workforce will become a standalone business called CVS Pharmacy, led by Prem Shah, currently the company's group president.

The market's first reaction was not polite. CVS shares closed at $79.96 on Wednesday, down about 12.5% from Tuesday's $91.41 close — before clawing back to $83.85 by Friday. For a company Reuters valued at roughly $117 billion before the news, that is a severe verdict on a plan management calls a move made "out of a position of strength."

Whatever the stock does next, the announcement closes a chapter. The idea that a drugstore chain could become the front door to all of American healthcare — the thesis behind one of the biggest deals of the last decade — is officially over.

The eight-year experiment

To understand what just ended, go back to 2018. That year, CVS completed its acquisition of Aetna, a deal worth about $78 billion including debt, and the American healthcare industry reorganized itself around a single idea: vertical integration. Own the insurer, the middleman that negotiates drug prices, and the store where the patient picks up the prescription, and you can manage the entire dollar as it moves through the system. Cigna bought Express Scripts the same year. UnitedHealth had already built the template with Optum.

CVS pushed the idea further than anyone with a retail footprint. It bought Oak Street Health's doctor offices and Signify Health's home-visit network. It put clinics inside stores. The strategy assumed the neighborhood drugstore would anchor everything — the physical touchpoint where insurance, pharmacy benefits, and care delivery all met the customer.

That is the assumption Wednesday's announcement abandons. The press release frames the split as giving each company "a focused strategic agenda" and "greater agility to innovate." Read plainly: the insurer and the PBM no longer believe they need to own the stores, and the stores no longer benefit from being a line item inside a conglomerate that Wall Street values on insurance margins.

Briefings like this are free to read with a free AlphaBriefing membership. Join free →

Why now

The timing is the interesting part, because CVS is not splitting in distress. On the same morning, the company reported third-quarter revenue of $108.4 billion, up from $102.87 billion a year earlier, beat Wall Street's expectations, and raised its full-year guidance. The stock had risen more than 50% since Joyner took over in October 2024 — from around $60 to above $91 — on the back of roughly $2 billion in cost cuts, store closures, and a repaired Medicare Advantage book at Aetna.

That strength is precisely the argument for acting now. CVS considered a breakup once before, in October 2024, and walked away; Joyner told CNBC the company was "in a turnaround" then, without the flexibility or cash position to execute one. Two years later, the board's "comprehensive strategic review" reached the opposite conclusion — a plan first reported by the Financial Times on Tuesday, a day before the official announcement.

There is also a regulatory undertow. Pharmacy benefit managers — Caremark is one of the three largest in the country, alongside Cigna's Express Scripts and UnitedHealth's Optum Rx — face mounting bipartisan scrutiny in Washington and in the states over opaque pricing and conflicts of interest. Tennessee and Arkansas have passed laws that would ban companies from owning both PBMs and pharmacies, laws CVS and others are fighting in court, per CNBC. A company that separates its PBM from its drugstores voluntarily is, among other things, getting ahead of the version of that separation a legislature might someday write for it.

Joyner insists the pieces will keep working together, telling analysts the synergies "are going to be preserved in commercial agreements between the two organizations." That is the open question investors are now pricing: whether a contract can replicate what common ownership did, and which side of the split needed the other more.

The drugstore stands alone

Step back from the deal mechanics and the announcement says something larger about American retail. The standalone drugstore — a storefront on every corner selling prescriptions, shampoo, and candy — spent the last decade being squeezed from every direction: reimbursement pressure on the pharmacy counter, Amazon and the dollar stores on the front of the store, theft and shrink, and the simple fact that the three big chains overbuilt for a world that stopped walking in.

The casualties are already on the books. Rite Aid went through bankruptcy twice and wound down its store network. Walgreens was taken private by Sycamore Partners in a deal Reuters valued at about $10 billion. CVS itself has been closing stores for years. When the split completes, CVS Pharmacy will be the last national drugstore chain standing as an independent public company — a pure-play bet on whether the physical pharmacy still matters in American healthcare.

The bull case for that company is real: prescription volumes keep growing, rivals' closures hand CVS market share, and a new cost-based reimbursement model the company calls CostVantage has, according to Leerink Partners analyst Michael Cherny, stabilized pharmacy margins that looked broken five years ago. The bear case is the last decade of drugstore history.

What to watch

Three things will determine how this ages. First, the fine print that hasn't been published yet: how the debt gets divided, what the commercial agreements between the two companies actually say, and who lands on each board — details CVS says are coming later. Second, the regulatory calendar, because the PBM bills moving through statehouses will shape the economics of the CVS Health side before the split even closes. Third, the 2028 timeline itself; separations of this size have a way of slowing down, and shareholders will hold both stocks through whatever happens in between.

The split is intended to be tax-free to shareholders, who will receive stock in both companies. Until the first half of 2028, they own what they have always owned — the whole thing. After that, the market gets to answer the question CVS spent $78 billion insisting it had already settled: whether the American drugstore is worth more inside a healthcare empire, or finally, on its own.

If this analysis was useful, this is what AlphaBriefing does every day — geopolitics and markets, connected to what it means for your money. A free membership gets you access to every free article on AlphaBriefing.com; paid members get the investment frameworks, scenario pricing, and catalyst calendars behind the paywall.

Sign up free → — upgrade whenever it earns it.

A free membership gets you access to every free article at AlphaBriefing.com: Join AlphaBriefing

Get this level of intelligence every day. Subscribe to AlphaBriefing — free, member, and paid tiers available.

Sources & Further Reading

Disclaimer

AlphaBriefing is an independent intelligence publication. The content in this article is produced for informational and educational purposes only. Nothing published by AlphaBriefing constitutes financial, investment, legal, tax, or regulatory advice, nor should it be construed as a solicitation or recommendation to buy, sell, or hold any security, asset, or financial instrument.

All views expressed are those of the author at the time of writing and are subject to change without notice. Markets are volatile and unpredictable; past performance is not indicative of future results. Any investment involves risk, including the possible loss of principal.

AlphaBriefing and its principals, employees, or contributors may hold positions in securities or assets mentioned in this article. This should be considered a potential conflict of interest. No material relationship with any company referenced exists unless explicitly disclosed. Readers should conduct their own due diligence and consult qualified financial, legal, and tax advisors before making any investment decisions.

Information in this article is drawn from public sources believed to be reliable at the time of publication. AlphaBriefing makes no warranty, express or implied, as to the accuracy, completeness, or timeliness of any information herein. AlphaBriefing accepts no liability for any loss or damage arising from reliance on this content.